We are a global clinical-stage biopharmaceutical company developing a new class of transformative medicines based on messenger ribonucleic acid that has the potential to improve the lives of people. Our current product portfolio includes CV8102, a cancer drug in a Phase 1 clinical trial to treat four types of solid tumors, and CV7202, a potential rabies vaccine in a Phase 1 clinical trial, and a potential COVID-19 (coronavirus or SARS-CoV-2) vaccine, for which we initiated a Phase 1 clinical trial in healthy volunteers in June 2020, with results expected in the fourth quarter of 2020.
Our vision is to revolutionize medicine and open new avenues for developing therapies by enabling the body to make its own drugs. Messenger ribonucleic acid, or mRNA, plays a central role in cellular biology in the production of proteins in every living cell. We are the pioneers in successfully harnessing mRNAs designed to prevent infections and to treat diseases by mimicking human biology to synthesize the desired proteins.
|Address||Friedrich-Miescher-Strasse 15, 72076 Tübingen, Germany|
|Phone Number||+49 7071 9883 0|
|View Prospectus:||CureVac B.V.|
|Revenues||$17.4 mil (last 12 months)|
|Net Income||$-102.4 mil (last 12 months)|
|Price range||$16.00 - $16.00|
|Est. $ Volume||$213.3 mil|
|Manager / Joint Managers||BofA Securities/ Jefferies/ Credit Suisse|
|CO-Managers||Berenberg/ Kempen & Co.|
|Expected To Trade:||8/14/2020|
|Quiet Period Expiration Date:||Available only to Subscribers|
|Lock-Up Period Expiration Date:||Available only to Subscribers|
|SCOOP Rating||Available only to Subscribers|
|Rating Change||Available only to Subscribers|